Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers

    Summary
    EudraCT number
    2019-003296-19
    Trial protocol
    ES   GB   DE  
    Global end of trial date
    24 Jun 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    27 Jul 2024
    First version publication date
    27 Jul 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    AFM24-101
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04259450
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Affimed GmbH
    Sponsor organisation address
    Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165
    Public contact
    Clinical Operations, Affimed GmbH, +49 621 560030, trials@affimed.com
    Scientific contact
    Clinical Operations, Affimed GmbH, +49 621 560030, trials@affimed.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Interim
    Date of interim/final analysis
    30 Sep 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    12 Jul 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    24 Jun 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    PHASE 1: Determine the maximum tolerated dose (MTD), select a recommended phase 2 dose (RP2D), and investigate the safety and tolerability of AFM24 in patients with advanced solid malignancies. PHASE 2a: Assess the preliminary anti-tumor efficacy of AFM24, using tumor response criteria as defined by local Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
    Protection of trial subjects
    Only eligible subjects that met all the study inclusion and none of the exclusion criteria could enter the study. Subjects could withdraw from the study at any time without stating a reason and without prejudice to further treatment. The investigator may have withdrawn a subject from the study and discontinued study drug and assessments at any time. The sponsor reserved the right to request withdrawal of a subject because of protocol violation or any other significant reason.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    20 Jan 2020
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety, Efficacy
    Long term follow-up duration
    3 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 25
    Country: Number of subjects enrolled
    United Kingdom: 9
    Country: Number of subjects enrolled
    Germany: 1
    Country: Number of subjects enrolled
    Korea, Republic of: 27
    Country: Number of subjects enrolled
    United States: 23
    Worldwide total number of subjects
    85
    EEA total number of subjects
    26
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    50
    From 65 to 84 years
    35
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    AFM24-101 was a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

    Pre-assignment
    Screening details
    Phase 1 subjects enrolled if they had a tumor known to express Epidermal Growth Factor Receptor (EGFR), Phase 2 subjects were screened for positive EGFR from tumor site. Specialists assessed the subjects, and they were enrolled in the study if they met all inclusion criteria and none of the exclusion criteria.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Phase 1- 14 mg Cohort 1
    Arm description
    Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Arm title
    Phase 1- 40 mg Cohort 2
    Arm description
    Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Arm title
    Phase 1- 80 mg Cohort 3
    Arm description
    Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Arm title
    Phase 1- 160 mg Cohort 4
    Arm description
    Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Arm title
    Phase 1- 320 mg Cohort 5
    Arm description
    Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Arm title
    Phase 1- 480 mg Cohort 6
    Arm description
    Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Arm title
    Phase 1- 720 mg Cohort 7
    Arm description
    Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Arm title
    Phase 2- CRC 480 mg Cohort A
    Arm description
    Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Arm title
    Phase 2- ccRCC 480 mg Cohort B
    Arm description
    Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who recieved 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Arm title
    Phase 2- NSCLC 480 mg Cohort C
    Arm description
    Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
    Arm type
    Experimental

    Investigational medicinal product name
    AFM24
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous AFM24 administrated 14 milligram weekly until disease progression, unacceptable toxicity, investigator discretion or withdrawal of consent.

    Number of subjects in period 1
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7 Phase 2- CRC 480 mg Cohort A Phase 2- ccRCC 480 mg Cohort B Phase 2- NSCLC 480 mg Cohort C
    Started
    2
    6
    4
    5
    6
    6
    6
    19
    8
    23
    Completed
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Not completed
    2
    6
    4
    5
    6
    6
    6
    19
    8
    23
         Adverse event, serious fatal
    -
    -
    -
    -
    -
    -
    -
    1
    1
    -
         on treatment
    -
    -
    -
    -
    -
    -
    -
    1
    1
    2
         Consent withdrawn by subject
    -
    -
    -
    -
    -
    -
    -
    1
    -
    -
         Disease progression
    2
    3
    4
    4
    6
    6
    6
    15
    6
    17
         Adverse event, non-fatal
    -
    3
    -
    1
    -
    -
    -
    1
    -
    3
         Other than listed
    -
    -
    -
    -
    -
    -
    -
    -
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Phase 1- 14 mg Cohort 1
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 40 mg Cohort 2
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 80 mg Cohort 3
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 160 mg Cohort 4
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 320 mg Cohort 5
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 480 mg Cohort 6
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 720 mg Cohort 7
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group title
    Phase 2- CRC 480 mg Cohort A
    Reporting group description
    Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group title
    Phase 2- ccRCC 480 mg Cohort B
    Reporting group description
    Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who recieved 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group title
    Phase 2- NSCLC 480 mg Cohort C
    Reporting group description
    Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7 Phase 2- CRC 480 mg Cohort A Phase 2- ccRCC 480 mg Cohort B Phase 2- NSCLC 480 mg Cohort C Total
    Number of subjects
    2 6 4 5 6 6 6 19 8 23 85
    Age categorical
    Units: Subjects
        In utero
    0 0 0 0 0 0 0 0 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0 0 0 0 0 0 0 0 0
        Newborns (0-27 days)
    0 0 0 0 0 0 0 0 0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0 0 0 0 0 0 0 0 0
        Children (2-11 years)
    0 0 0 0 0 0 0 0 0 0 0
        Adolescents (12-17 years)
    0 0 0 0 0 0 0 0 0 0 0
        Adults (18-64 years)
    0 4 3 4 3 4 6 10 3 13 50
        From 65-84 years
    2 2 1 1 3 2 0 9 5 10 35
        85 years and over
    0 0 0 0 0 0 0 0 0 0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    73.0 ( 0.0 ) 54.7 ( 14.12 ) 47.2 ( 20.89 ) 58.4 ( 11.35 ) 57.7 ( 16.99 ) 59.7 ( 12.08 ) 53.8 ( 10.57 ) 62.7 ( 9.32 ) 67.1 ( 15.0 ) 61.1 ( 11.83 ) -
    Gender categorical
    Units: Subjects
        Female
    1 1 0 4 3 2 1 5 2 10 29
        Male
    1 5 4 1 3 4 5 14 6 13 56
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    0 2 1 2 1 0 0 1 1 1 9
        Not Hispanic or Latino
    2 2 3 3 5 6 6 18 7 21 73
        Unknown or Not Reported
    0 2 0 0 0 0 0 0 0 1 3
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0 0 0 0 0 0 0 0 0
        Asian
    0 0 0 1 1 0 1 10 1 18 32
        Native Hawaiian or Other Pacific Islander
    0 0 0 0 0 0 0 0 0 0 0
        Black or African American
    1 0 0 0 1 0 0 0 0 0 2
        White
    1 4 4 4 4 5 5 9 7 5 48
        More than one race
    0 0 0 0 0 0 0 0 0 0 0
        Unknown or Not Reported
    0 2 0 0 0 1 0 0 0 0 3

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Phase 1- 14 mg Cohort 1
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 40 mg Cohort 2
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 80 mg Cohort 3
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 160 mg Cohort 4
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 320 mg Cohort 5
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 480 mg Cohort 6
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 720 mg Cohort 7
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group title
    Phase 2- CRC 480 mg Cohort A
    Reporting group description
    Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group title
    Phase 2- ccRCC 480 mg Cohort B
    Reporting group description
    Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who recieved 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group title
    Phase 2- NSCLC 480 mg Cohort C
    Reporting group description
    Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Primary: Phase 1: The Number of Subjects With Dose Limiting Toxicities (DLTs) During Cycle 1

    Close Top of page
    End point title
    Phase 1: The Number of Subjects With Dose Limiting Toxicities (DLTs) During Cycle 1 [1] [2]
    End point description
    The number of patients with dose limiting toxicities (DLTs) in the first cycle, as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. DLT is defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to underlying disease, disease progression, inter-current illness, or concomitant medications, that occurs ≤28 days following the first dose of AFM24 (Cycle 1). The Dose-Determining Set (DDS): All patients in the safety set (all patients who received at least one dose of AFM24), who had either (a) experienced DLT at any time during Cycle 1, or (b) met the minimum safety evaluation requirements without experiencing DLT within Cycle 1.
    End point type
    Primary
    End point timeframe
    During Cycle 1 (up to 28 days)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As per protocol, endpoint was only analyzed descriptively.
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    2
    4
    4
    4
    5
    6
    6
    Units: Participants
    0
    1
    0
    0
    0
    0
    0
    No statistical analyses for this end point

    Primary: Phase 2a: Overall Response Rate (Complete Response [CR] + Partial Response [PR])

    Close Top of page
    End point title
    Phase 2a: Overall Response Rate (Complete Response [CR] + Partial Response [PR]) [3] [4]
    End point description
    Overall response as defined by achieving confirmed CR and/or PR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial or complete response needs to be confirmed with repeated assessment at least 4 weeks after the initial assessment. The safety set: All patients who received at least one dose of AFM24.
    End point type
    Primary
    End point timeframe
    Up to approximately 16 weeks.
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 2 cohort.
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 2 cohort.
    End point values
    Phase 2- CRC 480 mg Cohort A Phase 2- ccRCC 480 mg Cohort B Phase 2- NSCLC 480 mg Cohort C
    Number of subjects analysed
    19
    8
    23
    Units: Participants
    0
    0
    2
    No statistical analyses for this end point

    Secondary: Phase 1: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

    Close Top of page
    End point title
    Phase 1: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) [5]
    End point description
    Adverse Events (AEs) will be summarized with patient counts by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes (SOCs) and Preferred Terms (PTs). The safety set: All patients who received at least one dose of AFM24.
    End point type
    Secondary
    End point timeframe
    From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.
    Notes
    [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    2
    6
    4
    5
    6
    6
    6
    Units: Participants
    2
    6
    4
    5
    6
    6
    6
    No statistical analyses for this end point

    Secondary: Phase 1: The Number of Subjects With Serious Adverse Events (SAEs)

    Close Top of page
    End point title
    Phase 1: The Number of Subjects With Serious Adverse Events (SAEs) [6]
    End point description
    Serious adverse Events (SAEs) will be summarized with patient counts by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes (SOCs) and Preferred Terms (PTs). The safety set: All patients who received at least one dose of AFM24.
    End point type
    Secondary
    End point timeframe
    From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.
    Notes
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    2
    6
    4
    5
    6
    6
    6
    Units: Participants
    2
    3
    2
    2
    4
    3
    2
    No statistical analyses for this end point

    Secondary: Phase 1: Area Under the Concentration-time Curve From Time 0 to Time Tau (7 Days) of AFM24 in Serum

    Close Top of page
    End point title
    Phase 1: Area Under the Concentration-time Curve From Time 0 to Time Tau (7 Days) of AFM24 in Serum [7]
    End point description
    Area under the concentration-time curve from time 0 to time tau (7 days) of AFM24 in serum(AUC0-168). The Pharmacokinetic set: all subjects who received at least one adequately documented dose of study drug and had at least one adequately documented post dose PK measurement. Subjects were excluded if they did not have at least two quantifiable concentration values, two of which must have occurred after Tmax, this was the case for one subject in Cohort 6.
    End point type
    Secondary
    End point timeframe
    Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 22.
    Notes
    [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    2
    3
    4
    4
    6
    5
    6
    Units: hours*nanogram /milliLiter
        arithmetic mean (standard deviation)
    53400 ( 61700 )
    549000 ( 254000 )
    1290000 ( 395000 )
    4940000 ( 1370000 )
    18100000 ( 6120000 )
    28700000 ( 7620000 )
    40200000 ( 12000000 )
    No statistical analyses for this end point

    Secondary: Phase 1: Maximum Plasma Concentration (Cmax) of AFM24

    Close Top of page
    End point title
    Phase 1: Maximum Plasma Concentration (Cmax) of AFM24 [8]
    End point description
    Maximum measured concentration (Cmax) of AFM24 in serum. The Pharmacokinetic set: all subjects who received at least one adequately documented dose of study drug and had at least one adequately documented post dose PK measurement.
    End point type
    Secondary
    End point timeframe
    Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 22.
    Notes
    [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    2
    3
    4
    4
    6
    6
    6
    Units: nanogram /milliLiter
        arithmetic mean (standard deviation)
    3290 ( 2860 )
    13200 ( 3100 )
    29200 ( 6620 )
    60900 ( 17600 )
    204000 ( 55600 )
    298000 ( 71100 )
    354000 ( 104000 )
    No statistical analyses for this end point

    Secondary: Phase 1: Time of Maximum Observed Concentration (Tmax) of AFM24

    Close Top of page
    End point title
    Phase 1: Time of Maximum Observed Concentration (Tmax) of AFM24 [9]
    End point description
    First time to maximum observed concentration of AFM24 sampled during a dosing interval. The Pharmacokinetic set: all subjects who received at least one adequately documented dose of study drug and had at least one adequately documented post dose PK measurement.
    End point type
    Secondary
    End point timeframe
    Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 22.
    Notes
    [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    2
    3
    4
    4
    6
    6
    6
    Units: hours
        arithmetic mean (standard deviation)
    1.84 ( 1.19 )
    3.43 ( 1.97 )
    5.63 ( 1.71 )
    5.64 ( 1.30 )
    7.18 ( 0.564 )
    7.52 ( 1.38 )
    5.21 ( 0.280 )
    No statistical analyses for this end point

    Secondary: Phase 1: Minimum Plasma Concentration (Cmin) of AFM24

    Close Top of page
    End point title
    Phase 1: Minimum Plasma Concentration (Cmin) of AFM24 [10]
    End point description
    Minimum measured concentration (Cmin) of AFM24 in serum. The Pharmacokinetic set: all subjects who received at least one adequately documented dose of study drug and had at least one adequately documented post dose PK measurement.
    End point type
    Secondary
    End point timeframe
    Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 22.
    Notes
    [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    2
    3
    4
    4
    6
    6
    6
    Units: ng/mL
        arithmetic mean (standard deviation)
    32.7 ( 46.2 )
    311 ( 281 )
    810 ( 482 )
    12000 ( 3540 )
    73800 ( 40600 )
    117000 ( 49600 )
    233000 ( 113000 )
    No statistical analyses for this end point

    Secondary: Phase 1: The number of subjects who developed anti-drug antibodies (ADAs) and neutralizing ADAs during treatment with AFM24

    Close Top of page
    End point title
    Phase 1: The number of subjects who developed anti-drug antibodies (ADAs) and neutralizing ADAs during treatment with AFM24 [11]
    End point description
    The number of subjects who developed anti-drug antibodies (ADAs) at any time during the study. The safety set: All patients who received at least one dose of AFM24.
    End point type
    Secondary
    End point timeframe
    Pre-dose cycle 1 Day 1 and end of treatment, up to approximately 39 weeks.
    Notes
    [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    0 [12]
    0 [13]
    0 [14]
    0 [15]
    0 [16]
    0 [17]
    0 [18]
    Units: Participants
    Notes
    [12] - Analysis is ongoing
    [13] - Analysis is ongoing
    [14] - Analysis is ongoing
    [15] - Analysis is ongoing
    [16] - Analysis is ongoing
    [17] - Analysis is ongoing
    [18] - Analysis is ongoing
    No statistical analyses for this end point

    Secondary: Phase 1: Overall Response Rate (Complete Response (CR) + Partial Response (PR))

    Close Top of page
    End point title
    Phase 1: Overall Response Rate (Complete Response (CR) + Partial Response (PR)) [19]
    End point description
    Overall response as defined by achieving confirmed CR and/or PR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial or complete response needs to be confirmed with repeated assessment at least 4 weeks after the initial assessment by local reader. The safety set: All patients who received at least one dose of AFM24.
    End point type
    Secondary
    End point timeframe
    From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.
    Notes
    [19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    2
    6
    4
    5
    6
    6
    6
    Units: Participants
    0
    0
    0
    0
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Phase 1: Disease Control Rate (Complete Response (CR) + Partial Response (PR) +Stable Disease (SD))

    Close Top of page
    End point title
    Phase 1: Disease Control Rate (Complete Response (CR) + Partial Response (PR) +Stable Disease (SD)) [20]
    End point description
    Disease control at months 3, 6, and 9, as defined by achieving CR and/or PR and/or SD assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The safety set: All patients who received at least one dose of AFM24.
    End point type
    Secondary
    End point timeframe
    From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.
    Notes
    [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    2
    6
    4
    5
    6
    6
    6
    Units: Participants
    0
    1
    0
    0
    0
    2
    1
    No statistical analyses for this end point

    Other pre-specified: Phase 1: Duration of Response Rate (DOR)

    Close Top of page
    End point title
    Phase 1: Duration of Response Rate (DOR) [21]
    End point description
    The DOR defined as time from first assessment of partial response (PR) or complete response (CR) to follow-on first assessment of progressive disease will be summarized by descriptive statistics including median DOR and where appropriate the respective 95% CIs. No subjects had a response.
    End point type
    Other pre-specified
    End point timeframe
    through study completion (estimated up to 24 weeks)
    Notes
    [21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1 cohort.
    End point values
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7
    Number of subjects analysed
    0 [22]
    0 [23]
    0 [24]
    0 [25]
    0 [26]
    0 [27]
    0 [28]
    Units: Participants
    Notes
    [22] - No data displayed because Outcome Measure has zero total participants analyzed.
    [23] - No data displayed because Outcome Measure has zero total participants analyzed.
    [24] - No data displayed because Outcome Measure has zero total participants analyzed.
    [25] - No data displayed because Outcome Measure has zero total participants analyzed.
    [26] - No data displayed because Outcome Measure has zero total participants analyzed.
    [27] - No data displayed because Outcome Measure has zero total participants analyzed.
    [28] - No data displayed because Outcome Measure has zero total participants analyzed.
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the start of first infusion till the last infusion + 30 days, up to approximately 68 weeks
    Adverse event reporting additional description
    The safety set consisted of all subjects who received at least one dose of AFM24.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    Phase 1- 14 mg Cohort 1
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 40 mg Cohort 2
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 80 mg Cohort 3
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 160 mg Cohort 4
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 320 mg Cohort 5
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 480 mg Cohort 6
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

    Reporting group title
    Phase 1- 720 mg Cohort 7
    Reporting group description
    Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group title
    Phase 2- CRC Cohort 1
    Reporting group description
    Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group title
    Phase 2- ccRCC Cohort 2
    Reporting group description
    Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who recieved 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Reporting group title
    Phase 2- NSCLC Cohort 3
    Reporting group description
    Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).

    Serious adverse events
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7 Phase 2- CRC Cohort 1 Phase 2- ccRCC Cohort 2 Phase 2- NSCLC Cohort 3
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 2 (100.00%)
    3 / 6 (50.00%)
    2 / 4 (50.00%)
    2 / 5 (40.00%)
    4 / 6 (66.67%)
    3 / 6 (50.00%)
    2 / 6 (33.33%)
    8 / 19 (42.11%)
    6 / 8 (75.00%)
    8 / 23 (34.78%)
         number of deaths (all causes)
    1
    6
    4
    3
    4
    4
    5
    14
    6
    5
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Metastatic neoplasm
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cancer pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Non-cardiac chest pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthenia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoxia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Productive cough
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tachypnoea
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    Pulmonary haemorrhage
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Injury, poisoning and procedural complications
    Hip fracture
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infusion related reaction
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    2 / 23 (8.70%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Myocardial infarction
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sinus tachycardia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sinus bradycardia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebral haemorrhage
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epilepsy
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Blindness
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholangitis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bile duct stenosis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dilatation intrahepatic duct acquired
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Jaundice cholestatic
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract obstruction
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Failure to thrive
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bone pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    COVID-19
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COVID-19 pneumonia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholangitis infective
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anorectal infection
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacterial abscess central nervous system
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oesophageal candidiasis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular device infection
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Phase 1- 14 mg Cohort 1 Phase 1- 40 mg Cohort 2 Phase 1- 80 mg Cohort 3 Phase 1- 160 mg Cohort 4 Phase 1- 320 mg Cohort 5 Phase 1- 480 mg Cohort 6 Phase 1- 720 mg Cohort 7 Phase 2- CRC Cohort 1 Phase 2- ccRCC Cohort 2 Phase 2- NSCLC Cohort 3
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    2 / 2 (100.00%)
    5 / 6 (83.33%)
    4 / 4 (100.00%)
    5 / 5 (100.00%)
    6 / 6 (100.00%)
    6 / 6 (100.00%)
    6 / 6 (100.00%)
    19 / 19 (100.00%)
    8 / 8 (100.00%)
    23 / 23 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Tumour pain
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    1
    0
    0
    0
    0
    0
    1
    0
    Acrochordon
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Cancer pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    1
    3
    0
    0
    0
    Hypotension
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    3
    1
    0
    Flushing
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    4
    0
    0
    0
    Deep vein thrombosis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    Hot flush
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    4 / 6 (66.67%)
    0 / 6 (0.00%)
    3 / 6 (50.00%)
    2 / 19 (10.53%)
    3 / 8 (37.50%)
    3 / 23 (13.04%)
         occurrences all number
    0
    1
    1
    0
    5
    0
    6
    2
    4
    3
    Pyrexia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    2 / 4 (50.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    4 / 19 (21.05%)
    0 / 8 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    5
    3
    0
    0
    2
    1
    4
    0
    2
    Asthenia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    4 / 19 (21.05%)
    2 / 8 (25.00%)
    3 / 23 (13.04%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    4
    5
    4
    Pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    1
    1
    1
    0
    Non-cardiac chest pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    0
    2
    Oedema peripheral
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    3 / 19 (15.79%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    3
    0
    0
    Chills
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    1
    0
    0
    0
    Chest discomfort
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Feeling of body temperature change
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Influenza like illness
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Infusion site extravasation
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Temperature regulation disorder
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Immune system disorders
    Cytokine release syndrome
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 6 (33.33%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    0
    0
    0
    0
    0
    0
    0
    0
    Reproductive system and breast disorders
    Testicular pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    3 / 6 (50.00%)
    1 / 6 (16.67%)
    2 / 19 (10.53%)
    0 / 8 (0.00%)
    3 / 23 (13.04%)
         occurrences all number
    1
    0
    0
    0
    0
    5
    1
    2
    0
    3
    Cough
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    5 / 23 (21.74%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    0
    6
    Epistaxis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    3
    0
    Haemoptysis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    Hiccups
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Pleural effusion
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    Rhinorrhoea
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    Tachypnoea
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Dysphonia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Dyspnoea exertional
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Hypoxia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Oropharyngeal pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Wheezing
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
    1 / 8 (12.50%)
    2 / 23 (8.70%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    1
    1
    1
    2
    Depression
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    1
    0
    Anxiety
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Confusional state
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Delirium
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 2 (0.00%)
    3 / 6 (50.00%)
    0 / 4 (0.00%)
    2 / 5 (40.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    3 / 6 (50.00%)
    2 / 19 (10.53%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    7
    0
    4
    0
    0
    5
    4
    1
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 2 (0.00%)
    3 / 6 (50.00%)
    1 / 4 (25.00%)
    2 / 5 (40.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    2 / 6 (33.33%)
    3 / 19 (15.79%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    7
    1
    3
    0
    0
    5
    4
    1
    0
    Blood pressure decreased
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    15
    0
    0
    0
    0
    0
    0
    0
    0
    Blood bilirubin increased
         subjects affected / exposed
    1 / 2 (50.00%)
    1 / 6 (16.67%)
    1 / 4 (25.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    3 / 19 (15.79%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    1
    3
    1
    2
    0
    0
    0
    4
    0
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 6 (33.33%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    3 / 6 (50.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    2
    2
    0
    3
    0
    0
    0
    Neutrophil count decreased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    5 / 23 (21.74%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    7
    Blood creatinine increased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    0
    2
    0
    Weight decreased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    2 / 6 (33.33%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    3
    0
    1
    0
    Platelet count decreased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    2
    0
    0
    White blood cell count decreased
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    0
    0
    0
    0
    0
    0
    0
    0
    Activated partial thromboplastin time prolonged
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Alpha tumour necrosis factor increased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    C-reactive protein increased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    International normalised ratio increased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Lipase increased
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Lymphocyte count decreased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Serum ferritin increased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Urine output decreased
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Injury, poisoning and procedural complications
    Infusion related reaction
         subjects affected / exposed
    1 / 2 (50.00%)
    5 / 6 (83.33%)
    3 / 4 (75.00%)
    4 / 5 (80.00%)
    3 / 6 (50.00%)
    6 / 6 (100.00%)
    4 / 6 (66.67%)
    15 / 19 (78.95%)
    5 / 8 (62.50%)
    19 / 23 (82.61%)
         occurrences all number
    4
    42
    4
    5
    4
    9
    5
    19
    5
    19
    Arthropod bite
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Clavicle fracture
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Fall
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Humerus fracture
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Radiation pneumonitis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Sunburn
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Congenital, familial and genetic disorders
    Hydrocele
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    2 / 5 (40.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    1
    0
    0
    0
    0
    Palpitations
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    3 / 5 (60.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
    2 / 8 (25.00%)
    3 / 23 (13.04%)
         occurrences all number
    0
    0
    1
    3
    2
    1
    2
    1
    3
    3
    Dizziness
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    3 / 6 (50.00%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
    0 / 8 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    1
    0
    1
    0
    3
    0
    2
    0
    2
    Peripheral sensory neuropathy
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    0
    0
    0
    0
    Aphasia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Bell's palsy
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Dysgeusia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Presyncope
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Somnolence
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Tremor
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Blood and lymphatic system disorders
    Lymphopenia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    2 / 6 (33.33%)
    1 / 6 (16.67%)
    3 / 19 (15.79%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    7
    12
    3
    5
    3
    0
    Anaemia
         subjects affected / exposed
    1 / 2 (50.00%)
    2 / 6 (33.33%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    4 / 19 (21.05%)
    1 / 8 (12.50%)
    2 / 23 (8.70%)
         occurrences all number
    1
    3
    0
    2
    3
    0
    1
    9
    1
    2
    Neutropenia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Thrombocytopenia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Eye disorders
    Chloropsia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    Vision blurred
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    2 / 6 (33.33%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    Conjunctival haemorrhage
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Diplopia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Eye pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Halo vision
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    2 / 2 (100.00%)
    1 / 6 (16.67%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    3 / 6 (50.00%)
    2 / 6 (33.33%)
    4 / 6 (66.67%)
    1 / 19 (5.26%)
    2 / 8 (25.00%)
    4 / 23 (17.39%)
         occurrences all number
    3
    1
    1
    0
    3
    2
    7
    1
    2
    4
    Constipation
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    2 / 6 (33.33%)
    1 / 6 (16.67%)
    3 / 6 (50.00%)
    4 / 19 (21.05%)
    3 / 8 (37.50%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    0
    2
    3
    3
    5
    3
    2
    Vomiting
         subjects affected / exposed
    1 / 2 (50.00%)
    2 / 6 (33.33%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    2 / 6 (33.33%)
    0 / 6 (0.00%)
    3 / 6 (50.00%)
    2 / 19 (10.53%)
    1 / 8 (12.50%)
    2 / 23 (8.70%)
         occurrences all number
    1
    2
    0
    0
    3
    0
    6
    2
    1
    2
    Diarrhoea
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    1 / 5 (20.00%)
    2 / 6 (33.33%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    1
    2
    1
    0
    2
    0
    0
    Abdominal distension
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    1
    0
    0
    1
    2
    1
    1
    0
    0
    0
    Abdominal pain
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 6 (33.33%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    3 / 19 (15.79%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    1
    0
    0
    3
    0
    0
    Abdominal discomfort
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    3 / 19 (15.79%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    1
    0
    Ascites
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    Dry mouth
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    1
    0
    0
    Proctalgia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Abdominal pain lower
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Abdominal pain upper
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Defaecation urgency
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Dyspepsia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Fistula of small intestine
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Inguinal hernia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Stomatitis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Toothache
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Hepatobiliary disorders
    Hepatic pain
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Jaundice
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Dermatitis acneiform
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    4 / 6 (66.67%)
    3 / 6 (50.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    3 / 23 (13.04%)
         occurrences all number
    0
    0
    1
    0
    1
    5
    5
    1
    0
    4
    Pruritus
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    2 / 6 (33.33%)
    4 / 19 (21.05%)
    2 / 8 (25.00%)
    3 / 23 (13.04%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    3
    6
    2
    3
    Rash maculo-papular
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    2
    0
    0
    1
    1
    1
    2
    0
    Rash
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    2 / 19 (10.53%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    3
    0
    0
    Dry skin
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Erythema
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Night sweats
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Rash macular
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Renal and urinary disorders
    Proteinuria
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    0
    1
    0
    0
    0
    0
    0
    0
    Dysuria
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    0
    0
    Haematuria
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 2 (0.00%)
    3 / 6 (50.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    3
    0
    0
    2
    0
    2
    1
    0
    Arthralgia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
    3 / 8 (37.50%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    1
    1
    3
    3
    Musculoskeletal chest pain
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    1
    0
    0
    0
    2
    0
    0
    0
    2
    Myalgia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    1
    2
    Muscle spasms
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    0
    0
    Pain in extremity
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    1
    0
    Axillary mass
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Bone pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Coccydynia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Flank pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Groin pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Musculoskeletal discomfort
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Neck pain
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Infections and infestations
    COVID-19
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    2 / 19 (10.53%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    2
    0
    0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0
    1
    0
    0
    0
    Urinary tract infection
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    1
    0
    Oral candidiasis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    1
    0
    Herpes zoster
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Klebsiella urinary tract infection
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Pneumonia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Rash pustular
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Rhinitis
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Skin infection
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Staphylococcal bacteraemia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Tooth infection
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Vascular device infection
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    1 / 2 (50.00%)
    1 / 6 (16.67%)
    1 / 4 (25.00%)
    1 / 5 (20.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    1 / 8 (12.50%)
    4 / 23 (17.39%)
         occurrences all number
    4
    2
    1
    1
    1
    1
    1
    2
    0
    3
    Hyponatraemia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    1 / 4 (25.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    2 / 6 (33.33%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    1
    0
    2
    0
    4
    0
    0
    0
    Hypoalbuminaemia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 6 (16.67%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    3
    0
    1
    1
    0
    0
    Dehydration
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    0 / 5 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    0
    0
    Hypocalcaemia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    0
    0
    Hypophosphataemia
         subjects affected / exposed
    0 / 2 (0.00%)
    0 / 6 (0.00%)
    0 / 4 (0.00%)
    1 / 5 (20.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
    0 / 8 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    04 Nov 2019
    A criterion to suspend further enrollment in study and performing safety analysis was added in case of occurrence of a Common Terminology Criteria for Adverse Events (CTCAE) Grade 5 event or a second CTCAE Grade 4 adverse event considered at least possibly related to AFM24 at any time during Phase 1 of the study. A criterion was added to permanently discontinue AFM24 in patients who experience dose-limiting toxicities (DLTs) during Cycle 1 treatment. a criterion was added to permanently discontinue AFM24 in patients who experience DLTs during Cycle 1 treatment. Some patients may experience cytokine release syndrome during or after the AFM24 infusion, and occurrence of such events (≥CTCAE Grade 3) will be considered a DLT for this study. Observation time has been clarified for patients experiencing such an event. General additional clarification in text, tables and figures.
    26 Mar 2020
    the objectives of the trial were re-worded to define more precise endpoints and increase clarity. Additional rules were applied for cases where the AFM24 treatment is interrupted or delayed, which were not covered previously. More detailed guidelines were created for Infusion Related Reaction, as previous language did not cover all aspects. Additionally, the protocol´s statistical section was updated to include more informative prior.
    16 Sep 2020
    The protocol was updated to introduce changes made to the premedication regimen for administration of AFM 24, as well as the guidance for the management of AFM 24 related infusion related reactions and other adverse events. In addition, the protocol was aligned with letter of amendment (LoA) submitted by the sponsor and guidance is added on infusion time to be followed during cycle 1 and subsequent cycles for management of IRRs. Also, additional safety follow-up visit was added after end-of treatment visit.
    16 Dec 2020
    The protocol was updated to for its patient populations to be included in the expansion cohorts of the Phase 2a of the study. The dose limiting toxicities (DLT) definitions are further clarified and the schedule/criteria are updated for collection of tumor biopsy samples. The statistical analysis for expansion phase (Phase 2a) are also revised per FDA guidelines on expansion cohorts for first-in-human (FIH) studies for expedited development on oncology drugs and biologics.
    03 May 2021
    The protocol was updated to add every-2-weeks (q2w) dosing for the dose expansion phase (Phase 2a) only. Additionally, split day dosing (infusion over 2 days) is also added for subjects who cannot tolerate the infusion over 4 hours. The protocol is also updated to include infusion related reactions (IRR) as an adverse event of special interest for AFM24, and to include more details on the monitoring and management of IRR including cytokine release syndrome (CRS).
    23 Dec 2021
    The protocol was updated to add clinical data available to date, justify the Recommended Phase II Dose (RP2D) and update of benefit risk section to reflect available clinical data. Furthermore, the inclusion criteria for phase 2 were aligned with regional requirements for standard of care.
    03 Nov 2022
    The protocol was updated to revise several inclusion and exclusion criteria for clarifications and alignment. In addition, the language related to the safety review by independent data monitoring committee (IDMC) for the expansion phase was amended. To align assessment of Overall Survival (OS), updates to the observation period and End of Study were added. A clarification was added regarding Adverse Event (AE) evaluation and Serious AEs (SAE) and AE of Special Interest (AESI) reporting requirements.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 21:48:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA